

**Wright Medical Group, Inc.**  
**Reconciliation of Net Sales to Net Sales Excluding the Impact of Foreign Currency**  
(dollars in thousands--unaudited)

**Three Months Ended**  
**March 31, 2014**

	<b>International Net Sales</b>	<b>Total Net Sales</b>
<b>Net sales, as reported</b>	\$ 22,111	\$ 71,062
Currency impact as compared to prior period	(30)	(30)
<b>Net sales, excluding the impact of foreign currency</b>	<b>\$ 22,081</b>	<b>\$ 71,032</b>

**Wright Medical Group, Inc.**  
**Reconciliation of As Reported Sales Growth to Non-GAAP Financial Measures**  
(unaudited)

**First Quarter 2014 Sales Growth/(Decline)**

	<b>As Reported Growth</b>	<b>Currency Impact</b>	<b>Constant Currency Growth</b>	<b>Acquisition Impact</b>	<b>Organic Growth</b>
<b>U.S.</b>					
Foot and Ankle	19%	0%	19%	11%	8%
Upper Extremity	(11%)	0%	(11%)	0%	(11%)
Biologics	7%	0%	7%	4%	3%
Other	138%	0%	138%	11%	127%
<b>Total U.S.</b>	<b>14%</b>	<b>0%</b>	<b>14%</b>	<b>8%</b>	<b>6%</b>
<b>International</b>					
Foot and Ankle	76%	2%	74%	35%	39%
Upper Extremity	45%	0%	45%	57%	(12%)
Biologics	40%	(7%)	47%	1%	46%
Other	80%	6%	74%	70%	4%
<b>Total International</b>	<b>63%</b>	<b>0%</b>	<b>63%</b>	<b>33%</b>	<b>30%</b>
<b>Global</b>					
Foot and Ankle	31%	0%	31%	16%	15%
Upper Extremity	7%	0%	7%	18%	(11%)
Biologics	15%	(1%)	16%	3%	13%
Other	97%	5%	92%	53%	39%
<b>Total Sales</b>	<b>26%</b>	<b>0%</b>	<b>26%</b>	<b>14%</b>	<b>12%</b>

**Wright Medical Group, Inc.**  
**Reconciliation of As Reported Results to Non-GAAP Financial Measures**  
(in thousands, except per share data--unaudited)

	<b>Three Months Ended</b>	
	<b>March 31, 2014</b>	<b>March 31, 2013</b>
<b>Operating Income</b>		
<b>Operating loss, as reported</b>	\$ (23,046)	\$ (13,226)
<i>Reconciling items impacting Gross Profit:</i>		
Inventory step-up amortization	604	108
<b>Total</b>	<b>604</b>	<b>108</b>
<i>Reconciling items impacting Selling, General and Administrative expense:</i>		
Distributor conversions	105	356
Transition costs - OrthoRecon divestiture	2,249	—
Due diligence, transaction and transition costs - acquisitions <sup>(1)</sup>	5,153	7,498
<b>Total</b>	<b>7,507</b>	<b>7,854</b>
<i>Reconciling items impacting Amortization of Intangible Assets:</i>		
Amortization of distributor non-competes	437	830
<b>Operating loss, as adjusted</b>	<b>\$ (14,498)</b>	<b>\$ (4,434)</b>
<b>Operating loss, as adjusted, as a percentage of net sales</b>	<b>(20.4)%</b>	<b>(7.9)%</b>

(1) For the three months ended March 31, 2013, amount includes \$2.3 million of non-cash stock-based compensation expense related to the conversion of BioMimetic options to Wright Medical options.

**Wright Medical Group, Inc.**  
**Reconciliation of As Reported Results to Non-GAAP Financial Measures**  
(in thousands, except per share data--unaudited)

	<b>Three Months Ended</b>	
	<b>March 31, 2014</b>	<b>March 31, 2013</b>
<b>EBITDA</b>		
<b>Net loss, as reported</b>	\$ (30,298)	\$ (4,918)
Interest expense, net	4,136	3,945
Benefit for income taxes	(12,170)	(6,404)
Depreciation	4,241	3,446
Amortization of intangible assets	2,187	1,606
<b>EBITDA</b>	<b>(31,904)</b>	<b>(2,325)</b>
<i>Reconciling items impacting EBITDA</i>		
Non-cash stock-based compensation expense <sup>(1)</sup>	2,320	1,613
Other expense (income), net	15,286	(5,849)
Inventory step-up amortization	604	108
Distributor conversions	105	356
Due diligence, transaction and transition costs	7,402	7,498
<b>Adjusted EBITDA</b>	<b>\$ (6,187)</b>	<b>\$ 1,401</b>
<b>Adjusted EBITDA as a percentage of net sales</b>	<b>(8.7)%</b>	<b>2.5%</b>

(1) For the three months ended March 31, 2013, amount excludes \$2.3 million of non-cash stock-based compensation expense related to the conversion of BioMimetic options to Wright Medical options, which is included in due diligence, transaction and transition costs.

**Wright Medical Group, Inc.**  
**Reconciliation of As Reported Results to Non-GAAP Financial Measures**  
(in thousands, except per share data--unaudited)

	<b>Three Months Ended</b>	
	<b>March 31, 2014</b>	<b>March 31, 2013</b>
<b>Net Income</b>		
<b>Loss before taxes, as reported</b>	\$ (42,468)	\$ (11,322)
<i>Pre-tax impact of reconciling items:</i>		
Inventory step-up amortization	604	108
Distributor conversion and non-competes	542	1,186
Non-cash interest expense on 2017 Convertible Notes	2,259	2,117
Derivatives mark-to-market adjustment	1,000	2,000
Transition costs - OrthoRecon divestiture	2,249	—
Due diligence, transaction and transition costs <sup>(1)</sup>	5,153	7,498
CVR mark-to-market adjustments	14,295	—
Gain on previously held investment in BioMimetic	—	(7,798)
<b>Loss before taxes, as adjusted</b>	<b>(16,366)</b>	<b>(6,211)</b>
<b>Benefit for income taxes, as reported</b>	<b>\$ (12,170)</b>	<b>\$ (6,404)</b>
U.S. tax benefit resulting from gain in discontinued operations	12,362	—
Inventory step-up amortization	—	42
Distributor conversion and non-competes	—	464
Non-cash interest expense on 2017 Convertible Notes	—	818
Derivatives mark-to-market adjustment	—	778
Due diligence, transaction and transition costs	—	1,438
<b>Provision (benefit) for income taxes, as adjusted</b>	<b>\$ 192</b>	<b>\$ (2,864)</b>
<b>Effective tax rate, as adjusted</b>	<b>(1.2)%</b>	<b>46.1%</b>
<b>Net loss, as adjusted</b>	<b>\$ (16,558)</b>	<b>\$ (3,347)</b>
<b>Weighted-average number of shares outstanding-diluted</b>	<b>48,625</b>	<b>41,438</b>
<b>Net loss from continuing operations, as adjusted, per diluted share</b>	<b>\$ (0.34)</b>	<b>\$ (0.08)</b>

(1) For the three months ended March 31, 2013, amount includes \$2.3 million of non-cash stock-based compensation expense related to the conversion of BioMimetic options to Wright Medical options.

**Wright Medical Group, Inc.**  
**Reconciliation of As Reported Results to Non-GAAP Financial Measures**  
**(continued)**

	<b>Three Months Ended</b>	
	<b>March 31, 2014</b>	<b>March 31, 2013</b>
<b>Net Income per Diluted Share</b>		
<b>Net loss from continuing operations, as reported, per diluted share</b>	\$ (0.62)	\$ (0.12)
U.S. tax benefit resulting from gain in discontinued operations	(0.25)	—
Inventory step-up amortization	0.01	0.00
Distributor conversion and non-competes	0.01	0.02
Non-cash interest expense on 2017 Convertible Notes	0.05	0.03
Derivatives mark-to-market adjustment	0.02	0.02
CVR mark-to-market adjustments	0.29	—
Transition costs - OrthoRecon divestiture	0.05	—
Due diligence, transaction and transition costs	0.11	0.15
Gain on previously held investment in BioMimetic	—	(0.19)
<b>Net loss from continuing operations, as adjusted, per diluted share <sup>(1)</sup></b>	<b>\$ (0.34)</b>	<b>\$ (0.08)</b>

(1) Reconciling items may not add to total net income, as adjusted, per diluted share due to rounding differences.

**Wright Medical Group, Inc.**  
**Reconciliation of Free Cash Flow**  
(dollars in thousands--unaudited)

	<b>Three Months Ended</b>	
	<b>March 31, 2014</b>	<b>March 31, 2013</b>
Net cash used in operating activities	\$ (27,240)	\$ (5,168)
Capital expenditures	(7,836)	(3,740)
Free cash flow	<u>\$ (35,076)</u>	<u>\$ (8,908)</u>